Aspira Women’s Health Reports Selected Third Quarter 2024

1 day ago · Q3 2024 OvaSuite S M revenue of $2.3 million and volume of 6,001 units. Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second …

12%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024

2 weeks from now

1 day ago · Q3 2024 OvaSuite S M revenue of $2.3 million and volume of 6,001 units. Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second …

globenewswire.com

$2
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024 …

2 weeks from now

1 day ago · Aspira Women's Health Inc. Q3 2024 OvaSuite S M revenue of $2.3 million and volume of 6,001 units. Cash utilization for the third quarter was $2.9 million, a decrease of …

yahoo.com

12%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024

2 weeks from now

1 day ago · Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units. Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second …

nasdaq.com

2%
OFF

2024-11-14 | Aspira Women's Health Reports Selected Third …

2 weeks from now

1 day ago · OvaSuite revenue for the third quarter of 2024 was $2.3 million, a 2% increase from $2.2 million in the same period last year and a slight decrease from $2.4 million in the second …

stockhouse.com

2%
OFF

Earnings Call: Aspira Women's Health Reports Steady Growth In Q3 …

2 weeks from now

1 day ago · Aspira Women's Health Incorporated (NASDAQ: AWH), a company specializing in women's health diagnostics, has reported a 2% increase in OvaSuite revenue to $2.3 million …

investing.com

2%
OFF

Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript

2 weeks from now

1 day ago · OvaSuite revenue for the third quarter of 2024 was $2.3 million, a 2% increase from $2.2 million of the same period last year and a slight decrease from $2.4 million in the second …

seekingalpha.com

2%
OFF

Earnings Call: Aspira Women's Health Reports Steady Growth In Q3 …

2 weeks from now

Aspira Women's Health Incorporated (NASDAQ: AWH), a company specializing in women's health diagnostics, has reported a 2% increase in OvaSuite revenue to $2.3 million for the …

investing.com

12%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024 …

2 weeks from now

1 day ago · Q3 2024 OvaSuite S M revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second …

businessinsider.com

2%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024 …

2 weeks from now

1 day ago · Aspira Women's Health reported Q3 2024 financial results with OvaSuite revenue of $2.3 million, representing a 2% increase year-over-year.Test volume grew 4% to 6,001 units, …

stocktitan.net

16%
OFF

Aspira Women’s Health Reports Second Quarter 2024 Financial …

2 weeks from now

Aug 12, 2024 · Q2 2024 cash utilization decreased by 16% compared to Q1 2024. Full year 2024 cash guidance decreased to $13-$14.5 million. Conference Call and Webcast scheduled for …

aspirawh.com

12%
OFF

Aspira Women's Health Reports Selected Third Quarter 2024 …

2 weeks from now

Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full …

quantisnow.com

12%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024 …

2 weeks from now

1 day ago · Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second …

marketscreener.com

$2
OFF

Aspira Women's Health Inc. (AWH) 8-K Earnings Release - Nov 2024

2 weeks from now

1 day ago · Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results . Q3 2024 OvaSuite SM revenue of $2.3 million and volume of 6,001 units . Cash utilization for the …

last10k.com

12%
OFF

Aspira Women’s Health Reports Selected Third Quarter 2024 …

2 weeks from now

November 14, 2024 08:00 ET Q3 2024 OvaSuite S M revenue of $2.3 million and volume of 6,001 units. Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to …

publicnow.com

FAQs about Aspira Women’s Health Reports Selected Third Quarter 2024 Coupon?

Who is in the ASPIRA Women's Health Inc conference call?

Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. ...

Why does ASPIRA women's health not make any forward-looking statements?

Due to the impact of many factors beyond Aspira Women's Health's Control. The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. ...

What is ARPA-H & ASPIRA doing with endoinform?

ARPA-H and Aspira are aligned on the criticality of focused investment in ENDOinform, with a goal of launching the diagnostic within the 2-year funding time frame. Along with this honor of being an award recipient, Aspira was named a spoke member of the Investor Catalyst Hub, led by the ARPA program director, VentureWell. ...

Why is Aspira a member of the investor Catalyst hub?

Along with this honor of being an award recipient, Aspira was named a spoke member of the Investor Catalyst Hub, led by the ARPA program director, VentureWell. This membership provides us with access to a vast network of nearly 600 members from key organizations across the private, public and non-profit sectors. ...

How do I contact aspirawh If I have a question?

If you have a question, please click on the question button at the bottom of your screen. If you have joined by phone and you have a question, please e-mail it to [email protected]. Question-and-Answer Session ...

How will ARPA-H funding affect endoinform and ovainform?

The ARPA-H funding will accelerate the expansion of the clinical study and we are also exploring options for purchasing additional samples to meet the required numbers for launch. We remain focused on advancing both ENDOinform and OVAinform as quickly as possible, based on the scientific progress and funding allocation. ...